Search

Displaying results 9851 - 9860 of 10000 in total
  1. Drug

    25-desacetylrifapentine

    go.drugbank.com/drugs/DB15213
    Investigational

    25-desacetylrifapentine is under investigation in clinical trial NCT00023387 (TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine).

  2. Drug

    Plamotamab

    go.drugbank.com/drugs/DB18944
    Investigational

    Plamotamab is under investigation in clinical trial NCT05328102 (Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (

  3. Drug

    Disitamab vedotin

    go.drugbank.com/drugs/DB17208
    Investigational

    Disitamab vedotin is an antibody-drug conjugate drug targeting human epidermal growth factor receptor 2 (HER2). It is currently being investigated for cancers.[A254721]

  4. Drug

    Ixmyelocel-T

    go.drugbank.com/drugs/DB17601
    Investigational

    Ixmyelocel-T is an expanded, autologous multicellular therapy cultured from bone-marrow mononuclear cells. Developed by Vericel Corporation, it is being investigated for cardiomyopathy.

  5. Drug

    Tetrahydrocannabivarin

    go.drugbank.com/drugs/DB11755
    Investigational

    In contrast, CB2 receptors are mainly found peripherally in immune cells, lymphoid tissue, and peripheral nerve terminals [A32676]. … Δ9-THC is currently available in several synthetic forms, including [Dronabinol], while purified or isolated THCV is not approved for any medical uses and is not available as any marketed products.

  6. Drug

    SR-9009

    go.drugbank.com/drugs/DB14013
    Experimental

    SR-9009 is a REV-ERB agonist. … SR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues

  7. Drug

    IDM-1

    go.drugbank.com/drugs/DB05292
    Experimental

    It is comprised of MAK(Monocytes-derived Activated Killer) cells associated with MDX-210, a bispecific anti-HER-2/neu antibody developed by Medarex Inc. … IDM-1 is IDM’s most advanced antibody-based Cell drug for the treatment of cancer.

  8. Drug

    Dezamizumab

    go.drugbank.com/drugs/DB15153
    Investigational

    Dezamizumab is under investigation in clinical trial NCT03417830 (Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging).

  9. Drug

    Fosravuconazole

    go.drugbank.com/drugs/DB15204
    Investigational

    Fosravuconazole is under investigation in clinical trial NCT03378661 (BENDITA BEnznidazole New Doses Improved Treatment and Associations).

  10. Drug

    Neodymium

    go.drugbank.com/drugs/DB15318
    Experimental

    Neodymium is under investigation in clinical trial NCT03525522 (Nd:Yttrium Aluminum Garnet Laser Treatment for Lichen Sclerosus).